NCT00891605 - Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Solid Tumors

Interventions

DRUG

ABT-263

150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

DRUG

paclitaxel

"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."